Nexlizet (Bempedoic acid and Ezetimibe) for Heart Disease | MyHeartDiseaseTeam

Connect with others who understand.

sign up Log in
About MyHeartDiseaseTeam
Powered By

Nexlizet is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Nexlizet is indicated as an adjunct therapy to diet and maximally-tolerated statin therapy. Nexlizet is a combination treatment of two drugs, bempedoic acid and ezetimibe.

Bempedoic acid is a member of the adenosine triphosphate-citrate lyase (ACL) inhibitor class of drugs. It is believed to work in cases of heart disease by inhibiting cholesterol production in the liver. Ezetimibe is a cholesterol absorption inhibitor. It is believed to work by blocking specific enzymes in the gastrointestinal tract, reducing cholesterol delivery to the liver. Both of these mechanisms lower the levels of LDL-C in the bloodstream.

How do I take it?
Prescribing information states that Nexlizet is taken orally as a tablet once daily.

Side effects
The FDA-approved label for Nexlizet lists common side effects including respiratory tract infection, muscle spasms, high blood uric acid levels, back pain, abdominal pain, bronchitis, low blood cell counts, elevated liver enzymes, diarrhea, joint pain, fatigue, and influenza.

A rare but serious side effect listed for Nexlizet is tendon rupture.

Nexlizet may cause adverse reactions when combined with certain other medications. Inform your doctor of any medications you take and any existing medical conditions before taking Nexlizet.

For more details about this treatment, visit:

Nexlizet — Esperion

Nexlizet —

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in